Friday
May202016

NCT02800811

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

First-in-human, phase I, randomized, double-blind, placebo-controlled, single center study evaluating single and multiple ascending intravenous doses of FR104 in healthy subjects.

Condition: Healthy Volunteers
Sponsor: OSE Immunotherapeutics
Phase 1 

Relates to J Immunol. 2016 Dec 15;197(12):4593-4602. Epub 2016 Nov 14.

PrintView Printer Friendly Version

EmailEmail Article to Friend